Rhineland-Palatinate administration collaborates with Boehringer Ingelheim: uniting efforts for our nation
That joint meeting at Boehringer Ingelheim with the Rhineland-Palatinate government was a game-changer. They got down to business, focused on beefing up Germany and Europe's competitive edge, all while ensuring societal stability. Boehringer's commitment to its location, the drive to expand biotechnology in Rhineland-Palatinate, the creation of good jobs, and investments in its site took center stage - Boehringer Ingelheim has dropped a whopping 2.3 billion euros on buildings and facilities in Germany alone in the last five years.
"We dig the regular, partnerly schmooze with Rhineland-Palatinate's cabinet on issues that matter to the land. We're all in on helping Germany's economy bounce back to prosperity. This baby needs some muscle from both the federal and state governments. The pharma industry is a heavyweight contender for Germany, and we're doing our best to pump up the economy," Médard Schoenmaeckers, Chairman of the Management Board of Boehringer Ingelheim in Germany, welcomed the guests with a bang.
"Rhineland-Palatinate is a frontrunner for biotechnology and the pharma industry in Germany. We've got a tight bond with companies like Boehringer Ingelheim, who set the bar with their commitment to the location and hefty investments in research and sustainable production. In these changing global times, as the state government, we gotta set the right stage.
"We’ve made some serious strides in recent years: With strategic investments in research infrastructure and universities, strong economic promotion, smart settlement management, and consistent bureaucracy reduction, we’re jacking up Rhineland-Palatinate as an innovation powerhouse. Simultaneously, we’re pushing for an attractive, sustainable production, industrial, and research location at both the national and EU levels.
"And we ain't forgetting about a united approach for the pharmaceutical industry in Europe. It's crucial that we boost competitiveness and resilience, even in light of international developments, and offer wide opportunities for research, development, and growth. Our goal is crystal clear: Rhineland-Palatinate should become the reigning champion for biotechnology - in close partnership between business, science, and politics,” said Minister President Alexander Schweitzer, Integration Minister Katharina Binz, and Economics Minister Daniela Schmitt.
"We need stable foundations for innovations in the health sector and biotechnology. A comprehensive healthcare, economic, and research policy is necessary to secure healthcare and strengthen the economy's resilience,” said Shashank Deshpande, member of the corporate management of Boehringer Ingelheim responsible for the human pharmaceuticals business area and designated chairman of the corporate management.
Boehringer Ingelheim: The Industry's Heavyweight
Boehringer Ingelheim, a biopharmaceutical powerhouse, dabbles in both human medicine and animal health. With a focus on innovative therapies in areas with high unmet medical need, the company pours resources into research and development. Lucky for them, their independence since its founding in 1885 has granted them a long-term perspective and an anchoring of sustainability along the entire value chain. With a workforce of over 54,500 employees, they cater to more than 130 markets with a vision of a healthier, more sustainable, and more equitable future. Learn more at www.boehringer-ingelheim.com.
Enrichment Insights
Boehringer Ingelheim: The company offers career and research opportunities to attract talent, inviting professionals to contribute to innovation in human and animal health. They also fund foundational research through initiatives like the "Rise up!-Programm," helping to accelerate drug discovery and development within the company.
Rhineland-Palatinate Government: The Ministry of Science and Health of Rhineland-Palatinate has awarded €1.3 million to the Institute of Molecular Biology (IMB) and the Centre for Healthy Ageing (CHA) in Mainz to establish the CoAGE doctoral training programme. The programme focuses on studying the causes of age-related diseases and multimorbidity, with a goal of improving healthy ageing. The state government also supports innovation in biomedical research through grants from initiatives such as the ReALity Innovation Fund.
While specific joint initiatives between Boehringer Ingelheim and the Rhineland-Palatinate government are not detailed in the provided sources, both are actively investing in research, innovation, and talent development to enhance the pharmaceutical industry’s competitiveness in Germany and Europe, according to relevant activities summarized above.
"Boehringer Ingelheim, being a heavyweight in the pharmaceutical industry, not only focuses on human medicine but also animal health, with a commitment to innovative therapies and sustainability along the entire value chain."
"The Rhineland-Palatinate government and Boehringer Ingelheim collaborate to foster research, talent development, and innovation within the pharmaceutical industry to strengthen Germany and Europe's competitive edge in this sector, while ensuring societal stability and promoting a healthier, more equitable future."
